Clinical Trial Update: An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 exploratory study evaluating Pertuzumab and Trastuzumab with Palbociclib and Exemestane as neoadjuvant therapy for triple-positive breast cancer; status…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Aromasin (exemestane)
• HERCEPTIN (trastuzumab)
• IBRANCE (PALBOCICLIB)
• Perjeta (pertuzumab)

Snippet

Sponsor: Anhui Provincial Cancer Hospital | Conditions: Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING